Medifast Inc

This advisory (non-binding) Say-on-Pay proposal asks shareholders to approve the Company’s disclosed fiscal 2025 executive compensation program, including the CD&A and compensation tables. Management seeks this approval to validate its compensation philosophy — which emphasizes pay-for-performance through a mix of base salary, quantitative short-term incentives (coach productivity and adjusted EBITDA) and long‑term performance-based and time-based equity awards — and to demonstrate alignment between executives and stockholders. The Company notes that the 2025 program incorporated changes in response to stockholder feedback (including adjustments to peer group composition, capped short-term incentive payouts, and modifications to long-term incentive structure) after the 2025 Say-on-Pay vote received approximately 59% support. The board recommends a vote FOR, arguing the program now more closely ties pay to realized performance, reduces certain payout levers during the transformation period, and includes governance safeguards such as clawback provisions, double-trigger change-in-control vesting, and stock ownership guidelines. Contextual governance factors include recent executive pay reductions for 2026 (notably a reduction in CEO target compensation), active shareholder outreach, and ongoing business transformation toward metabolic health, which management contends justifies the chosen performance metrics. The advisory nature of the vote means approval will not be binding, but the Board and Compensation Committee will consider the outcome when setting future compensation. For investors assessing this proposal, key considerations are the demonstrated responsiveness to prior shareholder dissent, the adequacy of the selected performance metrics to drive sustainable value (revenue, adjusted EBITDA, coach productivity), and whether structural changes materially reduce the potential for misalignment between pay and longer‑term total shareholder return. The recent use of modifiers (e.g., the 50% transformation modifier applied to 2025 bonuses) and capped payouts reflect conservative design choices during a volatile transition, but investors should weigh whether these temporary adjustments will persist as stability returns. Overall, the proposal is a governance checkpoint for shareholders to signal approval or concern regarding the Company’s compensation decisions and their alignment with long-term stockholder interests.

This proposal asks shareholders to approve a 250,000-share increase to the Amended and Restated 2012 Share Incentive Plan, expanding the pool available for equity compensation. Management argues the increase is necessary to continue granting equity awards to attract, retain and motivate employees and directors, citing historical burn rates and remaining share availability (approximately 547,381 shares as of December 31, 2025) as the basis for the request. The Compensation Committee considered outstanding awards, burn rate (7.6% in 2025 and a three-year average of 3.9%), and overhang (approximately 12.5% before the increase), concluding the additional shares are sufficient for near-term equity needs while keeping overhang at a manageable level (approximately 14.2% if approved). The proposal is presented in the context of recent frequent plan increases (515,000 in 2024 and 550,000 in 2025), which may signal higher-than-expected equity usage or aggressive retention/granting practices during the Company’s transformation; investors should scrutinize whether the Company’s grant practices are conservative and well-justified given the dilutionary effect. The plan includes several stockholder-protective features — no evergreen provision, double-trigger change-in-control vesting, minimum one-year vesting (with limited exceptions), prohibition on repricing without stockholder approval, and limits on director awards — which management highlights to mitigate dilution risk and align management with stockholders. From a governance and valuation perspective, the key issues for sophisticated investors are (i) the rationale for continued replenishment after two recent increases, (ii) the expected cadence and size of future grants under the refreshed equity program, (iii) the degree to which awards will be performance‑based versus time‑based, and (iv) the interaction between equity compensation and recent pay‑for‑performance concerns reflected in prior Say-on-Pay votes. The Board’s unanimous recommendation for approval reflects its view that the increase is necessary for competitive compensation practices during a strategic transformation, but investors should weigh this benefit against potential dilution and monitor grant pace and mix going forward.